Guided Therapeutics (GTHP) Shares Outstanding (Diluted Average) (2015 - 2025)
Guided Therapeutics recorded quarterly Shares Outstanding (Diluted Average) of $78.4 million in Q4 2025, down 4.01% quarter-over-quarter from $81.7 million in Q3 2025, and up 36.76% year-over-year from $57.3 million in Q4 2024.
Guided Therapeutics' Shares Outstanding (Diluted Average) history runs 11 years deep, the most recent figure standing at $78.4 million for Q4 2025.
- In Q4 2025, Shares Outstanding (Diluted Average) rose 36.76% year-over-year to $78.4 million; the TTM figure through Dec 2025 stood at $78.4 million (up 36.76% YoY), while the FY2025 annual figure was $78.4 million, up 36.76% from the prior year.
- Shares Outstanding (Diluted Average) came in at $78.4 million for Q4 2025 at Guided Therapeutics, down from $81.7 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $81.7 million in Q3 2025 to a low of $49297.0 in Q1 2023.
- A 5-year average of $42.3 million and a median of $50.4 million in 2023 frame the typical range for Shares Outstanding (Diluted Average).
- Across the five-year window, Shares Outstanding (Diluted Average) sank 99.76% in 2023 and jumped 110961.53% in 2024, its largest moves.
- Guided Therapeutics' Shares Outstanding (Diluted Average) stood at $13.4 million in 2021, then jumped by 142.99% to $32.5 million in 2022, then jumped by 57.3% to $51.1 million in 2023, then grew by 12.14% to $57.3 million in 2024, then jumped by 36.76% to $78.4 million in 2025.
- According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods registered $78.4 million, $81.7 million, and $73.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 1.75 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 386.50 Mn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 1.29 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 1.50 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 580.70 Mn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 393.60 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 457.00 Mn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Guided Therapeutics | - | - | 458,000.00 | 78.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 78.41 Mn |
| Sep 30, 2025 | 81.69 Mn |
| Jun 30, 2025 | 73.59 Mn |
| Mar 31, 2025 | 68.29 Mn |
| Dec 31, 2024 | 57.34 Mn |
| Sep 30, 2024 | 55.93 Mn |
| Jun 30, 2024 | 55.99 Mn |
| Mar 31, 2024 | 54.75 Mn |
| Dec 31, 2023 | 51.13 Mn |
| Sep 30, 2023 | 50.59 Mn |
| Jun 30, 2023 | 50.14 Mn |
| Mar 31, 2023 | 49,297.00 |
| Dec 31, 2022 | 32.51 Mn |
| Sep 30, 2022 | 34.83 Mn |
| Jun 30, 2022 | 26.34 Mn |
| Mar 31, 2022 | 20.68 Mn |
| Dec 31, 2021 | 13.38 Mn |
| Sep 30, 2021 | 13.42 Mn |
| Jun 30, 2021 | 13.28 Mn |
| Mar 31, 2021 | 13.17 Mn |
| Dec 31, 2020 | 10.77 Mn |
| Sep 30, 2020 | 60.33 Mn |
| Jun 30, 2020 | 11.91 Mn |
| Mar 31, 2020 | 65,620.00 |
| Dec 31, 2019 | 3,302.00 |
| Sep 30, 2019 | 3,296.00 |
| Jun 30, 2019 | 3,284.00 |
| Mar 31, 2019 | 3,248.00 |
| Dec 31, 2018 | 65,227.00 |
| Sep 30, 2018 | 394.00 |
| Jun 30, 2018 | 2,999.00 |
| Mar 31, 2018 | 2,493.00 |
| Sep 30, 2017 | 6,884.00 |
| Jun 30, 2017 | 1,434.00 |
| Mar 31, 2017 | 946.00 |
| Sep 30, 2016 | 114.00 |
| Jun 30, 2016 | 22.00 |
| Mar 31, 2016 | 109,899.00 |
| Sep 30, 2015 | 1.00 |
| Jun 30, 2015 | 107,256.00 |
| Mar 31, 2015 | 973.00 |